Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
A Brazilian research team has eliminated HIV from a patient’s body for 78 consecutive weeks using only medications, without ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The ...
BIC is an integrase strand transfer inhibitor that has a higher barrier to resistance and is only used in combination. LEN has been approved as a method of pre-exposure prophylaxis but has also been ...
Investing.com -- Gilead Sciences Inc (NASDAQ:GILD) stock rose 2.7% on Thursday after the company announced positive topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback